Evidence map›Paper›PMID 31655205›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2020

Nonviral polymeric nanoparticles for gene therapy in pediatric CNS malignancies.

John Choi, Yuan Rui, Jayoung Kim, Noah Gorelick, David R Wilson, Kristen Kozielski, Antonella Mangraviti, Eric Sankey, Henry Brem, Betty Tyler and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Advances in modification and delivery of nucleic acid drugs.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Review
  13. Review
  14. Article
  15. Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Nanotechnology in drug and gene delivery.Naunyn-Schmiedeberg's archives of pharmacology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

John ChoiDepartment of Neurosurgery, Johns Hopkins University School of Medicine.
Yuan RuiDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine.
Jayoung KimDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine.
Noah GorelickDepartment of Neurosurgery, Johns Hopkins University School of Medicine.
David R WilsonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine.
Kristen KozielskiDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine.
Antonella MangravitiDepartment of Neurosurgery, Johns Hopkins University School of Medicine.
Eric SankeyDepartment of Neurosurgery, Johns Hopkins University School of Medicine.
Henry BremDepartment of Neurosurgery, Johns Hopkins University School of Medicine; Department of Biomedical Engineering, Johns Hopkins University School of Medicine; Department of Ophthalmology, Johns Hopkins University School of Medicine; Department of Oncology, Johns Hopkins University School of Medicine.
Betty TylerDepartment of Neurosurgery, Johns Hopkins University School of Medicine.
Jordan J GreenDepartment of Neurosurgery, Johns Hopkins University School of Medicine; Department of Biomedical Engineering, Johns Hopkins University School of Medicine; The Institute for Nanobiotechnology and the Translational Tissue Engineering Center, Johns Hopkins University School of Medicine; Department of Ophthalmology, Johns Hopkins University School of Medicine; Department of Oncology, Johns Hopkins University School of Medicine; Department of Materials Science & Engineering, Johns Hopkins University; Department of Chemical & Biomolecular Engineering, Johns Hopkins University; Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine. Electronic address: green@jhu.edu.
Eric M JacksonDepartment of Neurosurgery, Johns Hopkins University School of Medicine. Electronic address: ejacks34@jhmi.edu.
Johns Hopkins University · USJohns Hopkins Medicine · USMaterials Science & Engineering · AU

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Jiang Qian · 1985 to 2026
$22.1M
BIOMEDICAL ENGINEERING TRAINING PROGRAMT32GM007057 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI KANOLD, PATRICK O, KARCHIN, RACHEL · 1985 to 2023
$10.4M
Gene Delivery Nanoparticles to Treat GlioblastomaR01CA228133 · NCI · JOHNS HOPKINS UNIVERSITY · PI GREEN, JORDAN · 2019 to 2023
$1.9M
NCI NIH HHS R01 CA228133NEI NIH HHS P30 EY001765NIGMS NIH HHS T32 GM007057
6 · The paper itself

Abstract

Together, medulloblastoma (MB) and atypical teratoid/rhabdoid tumors (AT/RT) represent two of the most prevalent pediatric brain malignancies. Current treatment involves radiation, which has high risks of developmental sequelae for patients under the age of three. New safer and more effective treatment modalities are needed. Cancer gene therapy is a promising alternative, but there are challenges with using viruses in pediatric patients. We developed a library of poly(beta-amino ester) (PBAE) nanoparticles and evaluated their efficacy for plasmid delivery of a suicide gene therapy to pediatric brain cancer models-specifically herpes simplex virus type I thymidine kinase (HSVtk), which results in controlled apoptosis of transfected cells. In vivo, PBAE-HSVtk treated groups had a greater median overall survival in mice implanted with AT/RT (P = 0.0083 vs. control) and MB (P < 0.0001 vs. control). Our data provide proof of principle for using biodegradable PBAE nanoparticles as a safe and effective nanomedicine for treating pediatric CNS malignancies.

Indexed as

Brain NeoplasmsGenetic TherapyHerpesvirus 1, HumanNanoparticlesThymidine KinaseViral ProteinsAnimalsCell Line, TumorChildHumansMaleMiceMice, NudeXenograft Model Antitumor AssaysThymidine KinaseViral ProteinsAtypical teratoid/rhabdoid tumorCancerMedulloblastomaPediatricsPoly(beta-amino ester) nanoparticle

Identifiers

PMID31655205
PMCPMC7027378
OpenAlexW2981893314

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.